Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Thursday

Taysha Gene Therapies (NASDAQ:TSHA) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $1.48 million for the quarter.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Trading Up 8.9%

Shares of NASDAQ:TSHA opened at $2.32 on Tuesday. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $4.32. The business’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.81. The company has a market capitalization of $475.73 million, a PE ratio of 3.68 and a beta of 0.90. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Analysts Set New Price Targets

TSHA has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.